1. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002; 29:2–9.
Article
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002; 346:235–42.
3. Pasa S, Altintas A, Cil T, Danis R, Ayyildiz O. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura. J Thromb Thrombolysis. 2009; 27:329–33.
Article
4. Allen KP, Funk AJ, Mandrell TD. Toxic epidermal necrolysis in two rhesus macaques (Macaca mulatta) after administration of rituximab. Comp Med. 2005; 55:377–81.
5. Schütt P, Passon J, Ebeling P, et al. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Eur J Haematol. 2007; 78:93–101.
Article
6. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994; 102:28S–30S.
Article
7. Revuz JE, Roujeau JC. Advances in toxic epidermal necrolysis. Semin Cutan Med Surg. 1996; 15:258–66.
Article
8. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003; 139:26–32.
9. Kimby E. Tolerability and safety of rituximab (Mab-Thera). Cancer Treat Rev. 2005; 31:456–73.
Article
10. Maeng CH, Chin SO, Yang BH, et al. A case of organizing pneumonia associated with rituximab. Cancer Res Treat. 2007; 39:88–91.
Article
11. Lee Y, Kyung SY, Choi SJ, et al. Two cases of interstitial pneumonitis caused by rituximab therapy. Korean J Intern Med. 2006; 21:183–6.
Article
12. Yi JH, Kim SJ, Ahn HK, Lee SJ, Chang MH, Kim WS. Rituximab-induced acute thrombocytopenia: a case report and review of the literature. Med Oncol. 2009; 26:45–8.
Article
13. Grillo-López AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol. 2002; 29:105–12.
Article
14. Foran JM, Gupta RK, Cunningham D, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol. 2000; 109:81–8.
Article
15. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol. 2002; 13:1948–50.
Article